Positive Phase IIb results under GeNeuro and Servier MS collaboration

Switzerland-based drug developer GeNeuro (Euronext Paris: GNRO) and French independent pharma company Servier today announced positive results at 12 months from the CHANGE-MS Phase IIb study of GNbAC1, a novel and promising therapeutic approach for the treatment of multiple sclerosis (MS).

The research was conducted as part of a 2014 collaboration worth a potential $455 million to the Swiss firm, whose share leapt 21.45% to 7.02 euros by mid-morning.

The data showed that GNbAC1 administration had a significant, consistent positive impact on key neuroprotection markers known to be linked to disease progression. This is the first time that the benefit of a treatment targeting endogenous retrovirus protein is shown in a clinical trial.